Also considered
14 papers judged, 2 emailed · Read the digest →
Final long-term survival update and exploratory subgroup analyses from the randomized phase II DEEPER trial comparing cetuximab- versus bevacizumab-based triplet chemotherapy in RAS/BRAF wild-type metastatic colorectal cancer, published in JCO. No overall survival/PFS difference in the main analysis, but exploratory signals favor cetuximab in left-sided, male, and extrahepatic-disease subgroups, informing but not changing first-line treatment selection.
Extended follow-up of a phase 1b expansion cohort combining an Fc-enhanced anti-CTLA-4 antibody with an anti-PD-1 antibody in heavily pretreated microsatellite-stable metastatic colorectal cancer without liver metastases, published in Clinical Cancer Research. Shows durable responses and encouraging survival in a population traditionally resistant to immunotherapy, supporting further development of this checkpoint combination.
Pan-Asian adaptation of the ESMO clinical practice guidelines for hepatocellular carcinoma, published in ESMO Open. Provides consensus recommendations for diagnosis, treatment, and follow-up of HCC tailored to Asian populations, directly informing systemic therapy decision-making.
Single-arm phase 1 trial adding oral L-glutamine to first-line gemcitabine/nab-paclitaxel in treatment-naive advanced pancreatic cancer, published in Nature Cancer. Shows a promising efficacy signal with tumor shrinkage and encouraging survival compared to historical controls, warranting further study.
Retrospective analysis in Eur J Cancer of a French national expert pathology network's 'third-reading' review process for difficult neuroendocrine neoplasm diagnoses. Shows expert re-review frequently reclassifies tumors in ways that fundamentally change treatment strategy, supporting referral for complex NEN pathology review.
Narrative review in JCO Precision Oncology synthesizing published case reports on sequencing FGFR inhibitors in FGFR-altered cholangiocarcinoma. Offers practical guidance on selecting later-line FGFR inhibitors based on mechanism and resistance patterns, though evidence is limited to case-level data.
Preclinical/translational study in gastric cancer, published in J Immunother Cancer, showing LASP1 loss disrupts cytoskeletal dynamics to blunt cytotoxic lymphocyte killing and predicts poorer response to anti-PD-1 therapy, with prognostic and predictive relevance confirmed in patient tissue.
Translational study in JNCI examining epigenetic aging clocks in normal, adjacent, and tumor colorectal tissue to characterize biological aging patterns associated with carcinogenesis. Purely mechanistic/biological with no specific therapeutic decision implications for oncologists.
Secondary/exploratory analysis of the phase III TOPGEAR trial evaluating perioperative chemotherapy with or without chemoradiotherapy in older versus younger adults with resectable gastric/GEJ cancer, published in Eur J Cancer. Suggests older patients tolerate treatment with more dose modifications but similar toxicity and comparable survival, supporting use of perioperative therapy in fit older patients.
Preclinical and translational study in Cancer Discovery identifying tumor-secreted ADAMTSL4 as a driver of cancer cachexia via TGFβ activation, with correlative data in colorectal and lung cancer patients. Suggests a potential future therapeutic target for cachexia but does not inform any current anticancer treatment decision.
Retrospective propensity-matched cohort study in chemorefractory microsatellite-stable metastatic colorectal cancer, published in J Immunother Cancer, comparing immune checkpoint inhibitors to standard salvage therapy and finding a survival benefit limited to patients without liver metastases, suggesting a possible niche for ICIs in this MSS subgroup.
Commentary/preview in Cancer Cell (Q1) discussing a large genomic study of colorectal cancer evolution and metastatic organ tropism. Offers a conceptual framework to refine surveillance rather than an immediate treatment change.
Large clinicogenomic analysis of over 7,000 colorectal cancer samples, published in Cancer Cell, characterizing genomic drivers and patterns of organ-specific metastatic spread. Offers biological insight into metastatic tropism but does not directly inform a specific therapeutic decision, limiting immediate clinical actionability.
Systematic review and meta-analysis in Lancet Gastroenterology & Hepatology estimating the diagnostic yield of germline multigene panel testing in unselected colorectal cancer patients. Informs decisions about routine genetic testing and identification of hereditary cancer syndromes in newly diagnosed patients.